The Canadian Food Inspection Agency has issued a recall for McCain's Tasti Taters brand Crispy Potato Bites due to the potential presence of plastic pieces in the food items. This recall is part of ongoing food safety measures to protect consumers from hazardous materials in food products.

Biogen's postpartum depression pill has received approval in Canada, marking a significant milestone as it becomes the first medication of its kind authorized in the country. This follows its approval in the United States, the U.K., and the European Union, where it has been available since late 2023.

Researchers are recommending the use of occipital nerve blocks in emergency rooms to treat acute migraine attacks, suggesting that this method can provide significant relief for patients suffering from severe migraines.

Health Canada has issued a recall for certain glucose monitors that may provide incorrect readings, urging diabetes patients to verify if their devices are affected by this international recall. This action highlights potential serious health risks associated with inaccurate blood sugar measurements.

A federal vaccine advisory committee in the U.S. has voted to discontinue the long-standing recommendation for all newborns to receive the hepatitis B vaccine at birth. This decision marks a significant shift in vaccination policy, reflecting ongoing debates about vaccine administration practices in the country.

Darlene Hensch, an Alberta mother who previously faced unexplained infertility, is now expecting quadruplets. She is preparing for a high-risk delivery, marking a significant and life-changing journey for her family.

Canada has implemented new restrictions on pistachios imported from Iran due to an ongoing salmonella outbreak, which has resulted in over 150 confirmed illnesses across the country. The Public Health Agency of Canada is actively investigating the situation as the outbreak continues to affect consumers.

Negotiations for the inclusion of Wegovy, a weight-loss drug developed by Novo Nordisk, in Canadian public drug plans have stalled as the company has refused to engage in discussions. This decision leaves many Canadians without access to this medication under public health coverage.